CADASIL: Experimental insights from animal models

Stroke

Volumn 41, Issue 10 SUPPL. 1, 2010, Pages

  Ayata, Cenk ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

CADASIL; leukoaraiosis; small vessel disease; vascular cognitive dysfunction

Indexed keywords

NOTCH3 RECEPTOR; NOTCH RECEPTOR; NOTCH3 PROTEIN, HUMAN;

BRAIN BLOOD FLOW; CADASIL; CLINICAL FEATURE; COGNITIVE DEFECT; CONFERENCE PAPER; DEMENTIA; DISEASE MODEL; GENE MUTATION; HUMAN; MIGRAINE WITH AURA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STROKE; SYMPTOM; TRANSGENIC MOUSE; WHITE MATTER; ANIMAL; GENETICS; KNOCKOUT MOUSE; MOUSE; PATHOLOGY;

ANIMALS; CADASIL; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, KNOCKOUT; RECEPTORS, NOTCH;

EID: 77958006065     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.595207     Document Type: Conference Paper

References (56)

1. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, Alamowitch S, Domenga V, Cecillion M, Marechal E, Maciazek J, Vayssiere C, Cruaud C, Cabanis EA, Ruchoux MM, Weissenbach J, Bach JF, Bousser MG, Tournier-Lasserve E. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383:707-710.
2. Tournier-Lasserve E, Joutel A, Melki J, Weissenbach J, Lathrop GM, Chabriat H, Mas JL, Cabanis EA, Baudrimont M, Maciazek J, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat Genet. 1993;3: 256-259.
3. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. Cadasil. Lancet Neurol. 2009;8:643-653.
4. Dong Y, Hassan A, Zhang Z, Huber D, Dalageorgou C, Markus HS. Yield of screening for cadasil mutations in lacunar stroke and leuko-araiosis. Stroke. 2003;34:203-205.
5. Adib-Samii P, Brice G, Martin RJ, Markus HS. Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. Stroke. 41:630-634.
6. Viswanathan A, Gschwendtner A, Guichard JP, Buffon F, Cumurciuc R, O'Sullivan M, Holtmannspotter M, Pachai C, Bousser MG, Dichgans M, Chabriat H. Lacunar lesions are independently associated with disability and cognitive impairment in CADASIL. Neurology. 2007;69:172-179.
7. Liem MK, van der Grond J, Haan J, van den Boom R, Ferrari MD, Knaap YM, Breuning MH, van Buchem MA, Middelkoop HA, Lesnik Oberstein SA. Lacunar infarcts are the main correlate with cognitive dysfunction in CADASIL. Stroke. 2007;38:923-928.
8. Lesnik Oberstein SA, van den Boom R, van Buchem MA, van Houwelingen HC, Bakker E, Vollebregt E, Ferrari MD, Breuning MH, Haan J. Cerebral microbleeds in CADASIL. Neurology. 2001;57:1066-1070.
9. Viswanathan A, Gray F, Bousser MG, Baudrimont M, Chabriat H. Cortical neuronal apoptosis in CADASIL. Stroke. 2006;37:2690-2695.
10. Tikka S, Mykkanen K, Ruchoux MM, Bergholm R, Junna M, Poyhonen M, Yki-Jarvinen H, Joutel A, Viitanen M, Baumann M, Kalimo H. Congruence between Notch3 mutations and GOM in 131 CADASIL patients. Brain. 2009;132:933-939.
11. Okeda R, Arima K, Kawai M. Arterial changes in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in relation to pathogenesis of diffuse myelin loss of cerebral white matter: examination of cerebral medullary arteries by reconstruction of serial sections of an autopsy case. Stroke. 2002;33: 2565-2569.
12. Yamamoto Y, Ihara M, Tham C, Low RW, Slade JY, Moss T, Oakley AE, Polvikoski T, Kalaria RN. Neuropathological correlates of temporal pole white matter hyperintensities in CADASIL. Stroke. 2009;40: 2004-2011.
13. Miao Q, Paloneva T, Tuominen S, Poyhonen M, Tuisku S, Viitanen M, Kalimo H. Fibrosis and stenosis of the long penetrating cerebral arteries: the cause of the white matter pathology in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Brain Pathol. 2004;14:358-364.
14. Bruening R, Dichgans M, Berchtenbreiter C, Yousry T, Seelos KC, Wu RH, Mayer M, Brix G, Reiser M. Cerebral autosomal dominant arteri-opathy with subcortical infarcts and leukoencephalopathy: decrease in regional cerebral blood volume in hyperintense subcortical lesions inversely correlates with disability and cognitive performance. AJNR Am J Neuroradiol. 2001;22:1268-1274.
15. Chabriat H, Pappata S, Ostergaard L, Clark CA, Pachot-Clouard M, Vahedi K, Jobert A, Le Bihan D, Bousser MG. Cerebral hemodynamics in CADASIL before and after acetazolamide challenge assessed with MRI bolus tracking. Stroke. 2000;31:1904-1912.
16. Pfefferkorn T, von Stuckrad-Barre S, Herzog J, Gasser T, Hamann GF, Dichgans M. Reduced cerebrovascular co(2) reactivity in CADASIL: a transcranial doppler sonography study. Stroke. 2001;32:17-21.
17. van den Boom R, Lesnik Oberstein SA, Spilt A, Behloul F, Ferrari MD, Haan J, Westendorp RG, van Buchem MA. Cerebral hemodynamics and white matter hyperintensities in CADASIL. J Cereb Blood Flow Metab. 2003;23:599-604.
18. Tuominen S, Miao Q, Kurki T, Tuisku S, Poyhonen M, Kalimo H, Viitanen M, Sipila HT, Bergman J, Rinne JO. Positron emission tomography examination of cerebral blood flow and glucose metabolism in young CADASIL patients. Stroke. 2004;35:1063-1067.
19. Peters N, Freilinger T, Opherk C, Pfefferkorn T, Dichgans M. Enhanced l-arginine-induced vasoreactivity suggests endothelial dysfunction in CADASIL. J Neurol. 2008;255:1203-1208.
20. Stenborg A, Kalimo H, Viitanen M, Terent A, Lind L. Impaired endo-thelial function of forearm resistance arteries in CADASIL patients. Stroke. 2007;38:2692-2697.
21. Ruchoux MM, Maurage CA. Endothelial changes in muscle and skin biopsies in patients with CADASIL. Neuropathol Appl Neurobiol. 1998; 24:60-65.
22. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284: 770-776.
23. Joutel A, Monet-Lepretre M, Gosele C, Baron-Menguy C, Hammes A, Schmidt S, Lemaire-Carrette B, Domenga V, Schedl A, Lacombe P, Hubner N. Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. J Clin Invest. 120:433-445.
24. Joutel A, Andreux F, Gaulis S, Domenga V, Cecillon M, Battail N, Piga N, Chapon F, Godfrain C, Tournier-Lasserve E. The ectodomain of the notch3 receptor accumulates within the cerebrovasculature of cadasil patients. J Clin Invest. 2000;105:597-605.
25. Peters N, Opherk C, Bergmann T, Castro M, Herzog J, Dichgans M. Spectrum of mutations in biopsy-proven CADASIL: implications for diagnostic strategies. Arch Neurol. 2005;62:1091-1094.
26. Joutel A, Vahedi K, Corpechot C, Troesch A, Chabriat H, Vayssiere C, Cruaud C, Maciazek J, Weissenbach J, Bousser MG, Bach JF, Tournier-Lasserve E. Strong clustering and stereotyped nature of notch3 mutations in CADASIL patients. Lancet. 1997;350:1511-1515.
27. Dichgans M, Ludwig H, Muller-Hocker J, Messerschmidt A, Gasser T. Small in-frame deletions and missense mutations in CADASIL: 3D models predict misfolding of Notch3 EGF-like repeat domains. Eur J Hum Genet. 2000;8:280-285.
28. Donahue CP, Kosik KS. Distribution pattern of Notch3 mutations suggests a gain-of-function mechanism for CADASIL. Genomics. 2004; 83:59-65.
29. Opherk C, Duering M, Peters N, Karpinska A, Rosner S, Schneider E, Bader B, Giese A, Dichgans M. CADASIL mutations enhance spontaneous multimerization of Notch3. Hum Mol Genet. 2009;18: 2761-2767.
30. Dichgans M, Filippi M, Bruning R, Iannucci G, Berchtenbreiter C, Minicucci L, Uttner I, Crispin A, Ludwig H, Gasser T, Yousry TA. Quantitative MRI in CADASIL: correlation with disability and cognitive performance. Neurology. 1999;52:1361-1367.
31. Dichgans M, Mayer M, Uttner I, Bruning R, Muller-Hocker J, Rungger G, Ebke M, Klockgether T, Gasser T. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol. 1998;44:731-739.
32. Singhal S, Bevan S, Barrick T, Rich P, Markus HS. The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain. 2004;127:2031-2038.
33. Karlstrom H, Beatus P, Dannaeus K, Chapman G, Lendahl U, Lundkvist J. A CADASIL-mutated notch 3 receptor exhibits impaired intracellular trafficking and maturation but normal ligand-induced signaling. Proc Natl Acad Sci U S A. 2002;99:17119-17124.
34. Peters N, Opherk C, Zacherle S, Capell A, Gempel P, Dichgans M. Cadasil-associated notch3 mutations have differential effects both on ligand binding and ligand-induced notch3 receptor signaling through rbp-jk. Exp Cell Res. 2004;299:454-464.
35. Joutel A, Monet M, Domenga V, Riant F, Tournier-Lasserve E. Pathogenic mutations associated with cerebral autosomal dominant arte-riopathy with subcortical infarcts and leukoencephalopathy differently affect jagged1 binding and notch3 activity via the rbp/jk signaling pathway. Am J Hum Genet. 2004;74:338-347.
36. Arboleda-Velasquez JF, Lopera F, Lopez E, Frosch MP, Sepulveda-Falla D, Gutierrez JE, Vargas S, Medina M, Martinez De Arrieta C, Lebo RV, Slaugenhaupt SA, Betensky RA, Villegas A, Arcos-Burgos M, Rivera D, Restrepo JC, Kosik KS. C455r notch3 mutation in a Colombian CADASIL kindred with early onset of stroke. Neurology. 2002;59: 277-279.
37. Monet-Lepretre M, Bardot B, Lemaire B, Domenga V, Godin O, Dichgans M, Tournier-Lasserve E, Cohen-Tannoudji M, Chabriat H, Joutel A. Distinct phenotypic and functional features of CADASIL mutations in the Notch3 ligand binding domain. Brain. 2009;132: 1601-1612.
38. Joutel A, Chabriat H, Vahedi K, Domenga V, Vayssiere C, Ruchoux MM, Lucas C, Leys D, Bousser MG, Tournier-Lasserve E. Splice site mutation causing a seven amino acid notch3 in-frame deletion in CADASIL. Neurology. 2000;54:1874-1875.
39. Opherk C, Peters N, Herzog J, Luedtke R, Dichgans M. Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain. 2004;127:2533-2539.
40. Krebs LT, Xue Y, Norton CR, Sundberg JP, Beatus P, Lendahl U, Joutel A, Gridley T. Characterization of Notch3-deficient mice: normal embryonic development and absence of genetic interactions with a Notch1 mutation. Genesis. 2003;37:139-143.
41. Arboleda-Velasquez JF, Zhou Z, Shin HK, Louvi A, Kim HH, Savitz SI, Liao JK, Salomone S, Ayata C, Moskowitz MA, Artavanis-Tsakonas S. Linking notch signaling to ischemic stroke. Proc Natl Acad Sci U S A. 2008;105:4856-4861.
42. Kitamoto T, Takahashi K, Takimoto H, Tomizuka K, Hayasaka M, Tabira T, Hanaoka K. Functional redundancy of the notch gene family during mouse embryogenesis: analysis of notch gene expression in Notch3-deficient mice. Biochem Biophys Res Commun. 2005;331:1154-1162.
43. Domenga V, Fardoux P, Lacombe P, Monet M, Maciazek J, Krebs LT, Klonjkowski B, Berrou E, Mericskay M, Li Z, Tournier-Lasserve E, Gridley T, Joutel A. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev. 2004;18:2730-2735.
44. Belin de Chantemele EJ, Retailleau K, Pinaud F, Vessieres E, Bocquet A, Guihot AL, Lemaire B, Domenga V, Baufreton C, Loufrani L, Joutel A, Henrion D. Notch3 is a major regulator of vascular tone in cerebral and tail resistance arteries. Arterioscler Thromb Vasc Biol. 2008;28: 2216-2224.
45. Mitchell KJ, Pinson KI, Kelly OG, Brennan J, Zupicich J, Scherz P, Leighton PA, Goodrich LV, Lu X, Avery BJ, Tate P, Dill K, Pangilinan E, Wakenight P, Tessier-Lavigne M, Skarnes WC. Functional analysis of secreted and transmembrane proteins critical to mouse development. Nat Genet. 2001;28:241-249.
46. Ruchoux MM, Domenga V, Brulin P, Maciazek J, Limol S, Tournier-Lasserve E, Joutel A. Transgenic mice expressing mutant notch3 develop vascular alterations characteristic of cerebral autosomal dominant arteri-opathy with subcortical infarcts and leukoencephalopathy. Am J Pathol. 2003;162:329-342.
47. Lundkvist J, Zhu S, Hansson EM, Schweinhardt P, Miao Q, Beatus P, Dannaeus K, Karlstrom H, Johansson CB, Viitanen M, Rozell B, Spenger C, Mohammed A, Kalimo H, Lendahl U. Mice carrying a r142c notch 3 knock-in mutation do not develop a cadasil-like phenotype. Genesis. 2005;41:13-22.
48. Dubroca C, Lacombe P, Domenga V, Maciazek J, Levy B, Tournier-Lasserve E, Joutel A, Henrion D. Impaired vascular mechanotransduction in a transgenic mouse model of cadasil arteriopathy. Stroke. 2005;36: 113-117.
49. Lacombe P, Oligo C, Domenga V, Tournier-Lasserve E, Joutel A. Impaired cerebral vasoreactivity in a transgenic mouse model of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoen-cephalopathy arteriopathy. Stroke. 2005;36:1053-1058.
50. Huang L, Yang Q, Zhang L, Chen X, Huang Q, Wang H. Acetazolamide improves cerebral hemodynamics in CADASIL. J Neurol Sci. 292: 77-80.
51. Liu H, Kennard S, Lilly B. Notch3 expression is induced in mural cells through an autoregulatory loop that requires endothelial-expressed jagged1. Circ Res. 2009;104:466-475.
52. Miao Q, Paloneva T, Tuisku S, Roine S, Poyhonen M, Viitanen M, Kalimo H. Arterioles of the lenticular nucleus in CADASIL. Stroke. 2006;37:2242-2247.
53. Miao Q, Kalimo H, Bogdanovic N, Kostulas K, Borjesson-Hanson A, Viitanen M. Cerebral arteriolar pathology in a 32-year-old patient with CADASIL. Neuropathol Appl Neurobiol. 2006;32:455-458.
54. Rufa A, Blardi P, De Lalla A, Cevenini G, De Stefano N, Zicari E, Auteri A, Federico A, Dotti MT. Plasma levels of asymmetric dimethylarginine in cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy. Cerebrovasc Dis. 2008;26:636-640.
55. Monet M, Domenga V, Lemaire B, Souilhol C, Langa F, Babinet C, Gridley T, Tournier-Lasserve E, Cohen-Tannoudji M, Joutel A. The archetypal r90c cadasil-notch3 mutation retains notch3 function in vivo. Hum Mol Genet. 2007.
56. Fouillade C, Chabriat H, Riant F, Mine M, Arnoud M, Magy L, Bousser MG, Tournier-Lasserve E, Joutel A. Activating notch3 mutation in a patient with small-vessel-disease of the brain. Hum Mutat. 2008;29:452.